Biofrontera Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BFRIW | FBIO | DERM | BIIB | LKFT | BLRX | |
|---|---|---|---|---|---|---|
| Market cap | — | 61.67M | 144.23M | 34.47B | 1.95B | 9.76M |
| P/E (TTM) | — | 0.7 | — | 41.4 | 2.8 | — |
| Forward P/E | — | -1.1 | -85.2 | 14.1 | -25.0 | -0.8 |
| Price/book | 0.0 | 0.4 | 4.4 | 1.8 | 10.7 | 0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | −32.25% | −31.33% | +58.66% | −13.06% | −46.26% |
| Today | 0.00% | −1.11% | +2.92% | +0.28% | −0.40% | −2.49% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All BFRIW news ›Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body
The Dermatology Digest Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body Ameluz PDT is currently FDA approved for AKs on the face and scalp and, since September 2026, for superficial basal cell carcinoma (sBCC). If…
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
The Phase 3 trial reported complete lesion clearance in 45.6% of Ameluz patients versus 16.7% with vehicle treatment. A randomized, vehicle-controlled Phase 3 trial enrolled 172 patients. Complete clearance of all treated lesions 12 weeks…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.